Please assess the completion status of the following clinical trial:

Trial Title: Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years old but \< 75 years old~* No HF hospitalization within 6 months~* Overweight or Obesity defined as BMI \> 29 but \< 42~* History of insulin resistance or T2DM and on oral diabetes agents other than SGLT2i (HgbA1c \> 5.8% and \< 10.5%)~* EF calculated based on a recent echo/cath/nuclear study at screening (pre-enrollment) \> 50%~* Stable HFpEF (HF with preserved ejection fraction) medications use of 3 months with no plans to changes or add medications for at least 12 weeks course of the study)~Exclusion Criteria:~* Acute HFpEF hospitalization within 6 months of enrollment.~* CKD stage 4 or 5 (eGFR \< 30 ml/min by CKD-EPI equation).~* Other known causes of HF including poorly controlled hypertension (SBP \>160 mm Hg) or ischemic cardiomyopathy (etc).~* Anemia (Hgb \< 11.0 mg/dL for women and \< 12.0 mg/dL for men) or severe thrombocytopenia (platelets \< 50,000 mm3)~* Anticipated changing of HF medication during anticipated study period.~* HFREF (LV EF \< 50%).~* Acute coronary syndrome, transient ischemic attack, CVA or critical limb ischemia during the last 6 months or coronary/peripheral revascularization within the last 3 months. Severe life threatening illness or live expectancy \< 6 months.~* Contraindications to MRI (metallic implants, severe claustrophobia) or treadmill exercise (limb amputation, severe osteoarthritis or equivalent functional mechanical limitation).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ertugliflozin Treatment Arm (Type: EXPERIMENTAL): Ertugliflozin 5 mg tablet once a day for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablet once a day for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).